Fundamentals in Urology Online Modules (2021)
The Fundamentals in Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. This course will provide attendees with valuable skills in developing a rational methodological approach to application of knowledge which will contribute to positive outcomes for patients.Attendees will discover the importance of the study of basic sciences and how it transfers into the lifelong learning process and medical practice. This course is designed to ensure a fundamental knowledge of the "why" behind a broad expanse of general urologic conditions. A thorough knowledge of the basic science behind the treatments will allow for better counseling and education of patients by all clinical urologic practitioners.
This course features enhanced programming that allows registrants to access additional online learning resources and modules at the convenience of their home for less time away from the office! The online modules include webcasts of content that was removed or reduced from the live program. The online educational modules will include the following content:
- Obstructive Uropathy
- Applications Outcome
- Renal Physiology
- Allied Health Professionals
After completing this activity, the learner will be able to:
- Review foundational concepts of bioethics.
- Define the meaning of “profession”.
- Discuss key aspects of consent, capacity, research and ethics.
- Identify how to apply consent, capacity, research and ethics to the practice of urology.
- Recognize the role of prophylacitic antibiotics and lower urinary tract imaging for prenatal urinary tract dilation.
- Recognize the validity of randomized clinical trials.
- Recognize how to apply the results of outcomes research to clinical practice.
- Discuss renal physiology for the urologist, especially for the following pathologic states: TUR syndrome, upper urinary tract obstruction, post-obstructive diuresis, pregnancy, renovascular hypertension, and juxtaglomerular tumor.
- Describe the common tumors and their top differential diagnoses in a given GU organ and clinic pathological setting.
- Identify the important pathological features, molecular alterations and behavior of common GU tumor entities.
- Interpret the latest classification schemes, contemporary grading practices and commonly used ancillary techniques in pathologic diagnosis.
- Determine the essential elements in the pathology reporting of common GU tumors and discuss their clinical relevance.
- Apply knowledge of lower urinary tract function and electronic measurement of pressure, flow and electromyography to performance of a multichannel urodynamic test including prestudy uroflowmetry, filling cystometrogram and voiding pressure flow study.
- Eric A. Singer, MD
- Charles D. Scales Jr., MD
- Necole Marie Streeper, MD
- Gladell Paner, MD
- Mikel Gray, PhD
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 8.5 hours
Release Date: June, 2021
Expiration Date: June, 2024
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring activity for a maximum of 8.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.